Abstract:1. The CMPK2 gene is highly expressed in the whole blood of sepsis patients. 2. A two‐step chemical tracking strategy was developed for the first time to identify and evaluate the inhibitor dracorhodin (DP) of CMPK2. 3. DP, as the first CMPK2 inhibitor, regulates the NLRP3 inflammasome by lipopolysaccharide (LPS)‐induced CMPK2 pathway in vivo and in vitro. Background Despite all modern advances in medicine, an effective drug for treating sepsis has yet to be found. The discovery of CMPK2 spurred hopes for the treatment of sepsis. However, CMPK2‐untapped target inhibitors are still an enormous obstacle that has hindered the CMPK2‐centric treatment of sepsis. Methods Here, we found that the CMPK2 gene is highly expressed in the whole blood of sepsis patients by RNA‐Seq. First, recombinant CMPK2 was purified by a eukaryotic expression purification system, and the activity of recombinant CMPK2 was detected by the ADP‐GLO assay. Second, we developed an affinity MS strategy combined with quantitative lysine reactivity profiling to discover CMPK2 ligands from the active ingredients of Chinese herbs. In addition, the dissociation constant Kd of the ligand and the target protein CMPK2 was further detected by microscale thermophoresis technology. Third, we used this strategy to identify a naturally sourced small molecule, dracorhodin (DP). Using mass spectrometry‐based quantitative lysine reactivity profiling combined with a series of mutant tests, the results show that K265 acts as a bright hotspot of DP inhibition of CMPK2. Fourth, immune‐histochemical staining, ELISAs, RT‐qPCR, flow cytometry and immunoblotting were used to illustrate the potential function and related mechanism of DP in regulating sepsis injury. Results Our results suggest that DP exerts powerful anti‐inflammatory effects by regulating the NLRP3 inflammasome via the lipopolysaccharide (LPS)‐induced CMPK2 pathway. Strikingly, DP significantly attenuated LPS‐induced sepsis in a mouse model, but its effect was weakened in mice with myeloid‐specific Cmpk2 ablation. Conclusion We provide a new framework that provides more valuable information for new therapeutic approaches to sepsis, including the establishment of screening strategies and the development of target drugs to provide a theoretical basis for ultimately improving clinical outcomes for sepsis patients. Collectively, these findings reveal that DP is a promising CMPK2 inhibitor for the treatment of sepsis.

KPT-330, a Potent and Selective CRM1 Inhibitor, Exhibits Anti-Inflammation Effects and Protection Against Sepsis

Discovery of Novel Pterostilbene Derivatives That Might Treat Sepsis by Attenuating Oxidative Stress and Inflammation Through Modulation of MAPKs/NF-κB Signaling Pathways

Inhibition of PI3K p110δ rebalanced Th17/Treg and reduced macrophages pyroptosis in LPS-induced sepsis

CM1, a Chrysin Derivative, Protects from Endotoxin-Induced Lethal Shock by Regulating the Excessive Activation of Inflammatory Responses

Development of Procathepsin L (pCTS-L)-Inhibiting Lanosterol-Carrying Liposome Nanoparticles to Treat Lethal Sepsis

Protectin Conjugates in Tissue Regeneration 1 Inhibits Macrophage Pyroptosis by Restricting NLRP3 Inflammasome Assembly to Mitigate Sepsis via the cAMP-PKA Pathway

CBP Bromodomain Inhibition Rescues Mice from Lethal Sepsis Through Blocking HMGB1-Mediated Inflammatory Responses

A novel triptolide derivative ZT01 exerts anti-inflammatory effects by targeting TAK1 to prevent macrophage polarization into pro-inflammatory phenotype

The Antimicrobial Peptide Chensinin-1B Alleviates the Inflammatory Response by Targeting the TLR4/NF-κB Signaling Pathway and Inhibits Pseudomonas Aeruginosa Infection and LPS-mediated Sepsis.

Bioactive compound C498-0670 alleviates LPS-induced sepsis via JAK/STAT and NFκB signaling pathways

Protective Effect of a Novel RIPK1 Inhibitor, Compound 4–155, in Systemic Inflammatory Response Syndrome and Sepsis

Puerarin Increases Survival and Protects Against Organ Injury by Suppressing NF-κB/JNK Signaling in Experimental Sepsis

Dracorhodin targeting CMPK2 attenuates inflammation: A novel approach to sepsis therapy

Capsaicin Ameliorates Inflammation in a TRPV1-independent Mechanism by Inhibiting PKM2-LDHA-mediated Warburg Effect in Sepsis.

Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activated receptor-gamma

Protectin conjugates in tissue regeneration 1 restores lipopolysaccharide-induced pulmonary endothelial glycocalyx loss via ALX/SIRT1/NF-kappa B axis

Topotecan Reduces Sepsis‐induced Acute Lung Injury and Decreases the Inflammatory Response Via the Inhibition of the NF‐κB Signaling Pathway

UMI-77 Modulates the Complement Cascade Pathway and Inhibits Inflammatory Factor Storm in Sepsis Based on TMT Proteomics and Inflammation Array Glass Chip

Therapeutic potential of procathepsin L-inhibiting and progesterone-entrapping dimethyl-β-cyclodextrin nanoparticles in treating experimental sepsis

Kukoamine B, A Novel Dual Inhibitor of Lps and Cpg Dna, is A Potential Candidate for Sepsis Treatment

CTRP4 Acts As an Anti-Inflammatory Factor in Macrophages and Protects Against Endotoxic Shock